Qube Research & Technologies Ltd Invests $317,000 in Exelixis, Inc. (NASDAQ:EXEL)

Qube Research & Technologies Ltd acquired a new position in Exelixis, Inc. (NASDAQ:EXEL) during the 2nd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund acquired 14,832 shares of the biotechnology company’s stock, valued at approximately $317,000.

Several other institutional investors and hedge funds also recently added to or reduced their stakes in EXEL. Swiss National Bank grew its holdings in shares of Exelixis by 2.5% during the 2nd quarter. Swiss National Bank now owns 558,500 shares of the biotechnology company’s stock worth $11,935,000 after acquiring an additional 13,600 shares during the period. Candriam Luxembourg S.C.A. grew its holdings in shares of Exelixis by 3.4% during the 2nd quarter. Candriam Luxembourg S.C.A. now owns 737,342 shares of the biotechnology company’s stock worth $15,688,000 after acquiring an additional 24,200 shares during the period. Stephens Investment Management Group LLC grew its holdings in shares of Exelixis by 0.8% during the 2nd quarter. Stephens Investment Management Group LLC now owns 848,571 shares of the biotechnology company’s stock worth $18,134,000 after acquiring an additional 6,827 shares during the period. DekaBank Deutsche Girozentrale grew its holdings in shares of Exelixis by 74.5% during the 2nd quarter. DekaBank Deutsche Girozentrale now owns 206,400 shares of the biotechnology company’s stock worth $4,427,000 after acquiring an additional 88,100 shares during the period. Finally, Stanley Laman Group Ltd. purchased a new position in shares of Exelixis during the 2nd quarter worth approximately $263,000. Hedge funds and other institutional investors own 76.79% of the company’s stock.

Shares of EXEL traded down $0.49 during mid-day trading on Wednesday, reaching $21.27. The company had a trading volume of 41,427 shares, compared to its average volume of 2,750,317. The company has a debt-to-equity ratio of 0.02, a quick ratio of 8.53 and a current ratio of 8.64. The firm has a 50-day moving average price of $20.93 and a 200 day moving average price of $21.52. Exelixis, Inc. has a 52 week low of $13.42 and a 52 week high of $25.31. The company has a market capitalization of $6.58 billion, a price-to-earnings ratio of 14.80 and a beta of 1.98.

Exelixis (NASDAQ:EXEL) last issued its quarterly earnings results on Wednesday, July 31st. The biotechnology company reported $0.25 EPS for the quarter, topping analysts’ consensus estimates of $0.23 by $0.02. Exelixis had a return on equity of 31.31% and a net margin of 70.52%. The firm had revenue of $240.28 million for the quarter, compared to analysts’ expectations of $226.97 million. During the same period in the previous year, the firm posted $0.31 EPS. The business’s revenue for the quarter was up 29.1% compared to the same quarter last year. As a group, research analysts forecast that Exelixis, Inc. will post 0.89 earnings per share for the current fiscal year.

In other news, Director George A. Scangos sold 40,000 shares of the business’s stock in a transaction that occurred on Tuesday, June 4th. The stock was sold at an average price of $19.76, for a total value of $790,400.00. Following the sale, the director now directly owns 1,223,031 shares of the company’s stock, valued at approximately $24,167,092.56. The sale was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, EVP Jeffrey Hessekiel sold 75,000 shares of the business’s stock in a transaction that occurred on Friday, August 16th. The stock was sold at an average price of $21.10, for a total value of $1,582,500.00. The disclosure for this sale can be found here. Over the last three months, insiders sold 652,522 shares of company stock worth $13,461,761. Insiders own 4.50% of the company’s stock.

A number of research firms have weighed in on EXEL. Cowen set a $25.00 target price on Exelixis and gave the stock a “buy” rating in a report on Wednesday, July 31st. Zacks Investment Research upgraded Exelixis from a “hold” rating to a “buy” rating and set a $23.00 target price on the stock in a report on Tuesday, August 6th. ValuEngine downgraded Exelixis from a “hold” rating to a “sell” rating in a report on Wednesday, July 24th. Stifel Nicolaus upped their target price on Exelixis from $22.00 to $23.00 and gave the stock a “hold” rating in a report on Thursday, August 1st. Finally, Morgan Stanley set a $27.00 target price on Exelixis and gave the stock a “hold” rating in a report on Thursday, May 2nd. One investment analyst has rated the stock with a sell rating, five have issued a hold rating and five have given a buy rating to the stock. The company presently has a consensus rating of “Hold” and a consensus price target of $27.75.

Exelixis Profile

Exelixis, Inc, an oncology-focused biotechnology company, focuses on the discovery, development, and commercialization of new medicines to treat cancers in the United States. The company's products include CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of patients with progressive and metastatic medullary thyroid cancer.

Featured Article: Average Daily Trade Volume Explained

Want to see what other hedge funds are holding EXEL? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Exelixis, Inc. (NASDAQ:EXEL).

Institutional Ownership by Quarter for Exelixis (NASDAQ:EXEL)

Receive News & Ratings for Exelixis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Exelixis and related companies with MarketBeat.com's FREE daily email newsletter.